The hippocampus, a part of the limbic system, is found to be necessary for several types of learning and memory formation in rats and other mammals (
1,
2). The
N-methyl-D-aspartate receptor (NMDAR) which is highly expressed in the hippocampus is implicated in some types of long term potentiation (LTP) that might underlie spatial learning and memory (
3).
Cyclooxygenase (COX) is the key enzyme that converts arachidonic acid (AA) to prostaglandins (PGs) and the target enzyme of nonsteroidal antiinflammatory drugs (NSAID) (
4). Cyclooxygenase isoform, cyclooxygenase-1 (COX-1) is the constitutive form of cyclooxygenase and performs a housekeeping function to synthesize PGs, involved in regulating normal cellular activities (
4-
8). In contrast, the COX-2 promoter is not basally active in most cell types, but can be strongly and rapidly induced by growth factors and proinflammatory mediators (
9,
10). The brain expresses both the isoforms. COX-2 is expressed in discrete populations of neurons and is enriched in the cortex and hippocampus (
11) and has been implicated in brain functions and in neurologic disorders, including stroke, seizures, and Alzheimer’s Disease (AD) (
5,
12). Within the hippocampus, COX-2 protein is observed especially where the glutamatergic neurons are selectively colocalized (
6) and neuronal COX-2 expression appears to be coupled to excitatory neuronal activity which is suggested to be dependent on NMDAR activity (
13,
14). Previous research has employed different kinds of NSAIDs (piroxicam, NS-398, celecoxib, indomethasin) to examine the effect on spatial memory in rats. The results support the idea that COX-2 is probably involved in the physiological mechanisms underlying memory formation (
4,
8,
11). Although COX-2 appears to facilitate cognition under normal conditions, studies in the aged rats suggests that dysregulation or overexpression of COX-2 function is detrimental to memory consolidation (
15-
17). Recent studies have also indicated that in addition to the overexpression of COX-2 mRNA and protein (
18), COX-1 has a previously unrecognized proinflammatory role in the pathophysiology of acute and chronic neurological disorders such as AD, Parkinson Disease, HIV-associated dementia (
19-
21). A selective increase in COX-1 mRNA expression in the hippocampus of aged rats was shown which was possibly causing an increased susceptibility to neuroinflammation (
22) and also COX-1-expressing microglia are found surrounding the amyloid plaques in the AD brain indicating a role of this isoform in the pathophysiology of the disease (
21,
23).
Based on the compelling evidence that inflammatory processes are involved in the pathogenesis of AD, it has been hypothesized that NSAIDs might slow the onset and progression of AD (
24,
25). For this purpose ibuprofen has been used in many clinical and experimental investigations and some benefial effects on AD related pathological constituents such as reduction of the
β amiloid plaques and amyloid precursor protein (
26-
32) and blockade of Rho protein (
29,
33) has been demostrated. Studies with nimesulide in rodents indicate that the inhibition of COX-2 activity attenuates brain inflammation associated with excitotoxic damage (
34,
35). Aisen
et al. reported that nimesulide has no short-term cognitive or behavioral toxicity, nor any clear symptomatic benefit on the manifestations of AD (
36). However, the subchronic effects of ibuprofen and also nimesulide on spatial memory in aged brain and their probable effects on NMDARs hasn’t been investigated.
In this study we investigated the effects of subchronic administration of ibuprofen as a non-selective COX inhibitor and nimesulide as a selective COX-2 inhibitor, on spatial memory in the eight arm radial maze. In addition, the effect of drug treatment on protein expression of NR2A and NR2B, the subunits of NMDARs, was examined.